In phase III studies with the first SGLT2 inhibitor that was applied for marketing authorization, dapagliflozin, a marked numerical imbalance in the cases of bladder cancer was observed between the dapagliflozin and comparator groups; however, the number of cases was low. This evidence concerns the gene SLC5A2 and urinary bladder cancer.